Background Since the 1960s, beta blockers have been used to treat hypertrophic obstructive cardiomyopathy (HOCM), a genetic ...

Please provide your email address to receive an email when new articles are posted on . In patients with nonobstructive hypertrophic cardiomyopathy, treatment with mavacamten was well tolerated and ...

The emergence of novel pharmacotherapies, minimally-invasive procedures and gene-directed approaches shall fundamentally alter the Hypertrophic Cardiomyopathy therapeutic landscape. Amongst all ...

The Hypertrophic Cardiomyopathy (HCM) Program at University of Utah Health is one of the nation’s few programs for comprehensive HCM evaluation and management. Our multidisciplinary team works ...

Please provide your email address to receive an email when new articles are posted on . “Shared decision-making, a dialogue between patients and their care team that includes full disclosure of all ...

Hypertrophic cardiomyopathy (HCM) is the most common hereditary heart disease. It causes the left ventricle to thicken, the ...

For patients with hypertrophic cardiomyopathy that doesn’t improve with standard therapy, surgery may be the next choice. In France, a new study was conducted to compare the incidence of in-hospital ...

In a move greatly welcomed by heart charities, the National Institute for Health and Care Excellence (NICE) has approved mavacamten for treating symptomatic obstructive hypertrophic cardiomyopathy ...

Hypertrophic Cardiomyopathy Medical Society Scientific Sessions Title: Effect of Aficamten vs Metoprolol on Patient-Reported Health Status in Obstructive Hypertrophic Cardiomyopathy Presenter: Michael ...

This transcript has been edited for clarity. For more episodes, download the Medscape app or subscribe to the podcast on Apple Podcasts, Spotify, or your preferred podcast provider. Carolyn Ho, MD: ...

Background A 48-year-old man with hypertrophic obstructive cardiomyopathy (HOCM) presented with palpitations, symptoms of medically refractory class II angina, and NYHA class II–III heart failure.